{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:37Z","timestamp":1793406877971,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.dsx.2022.102680","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:53:47Z","timestamp":1669596827000},"page":"102680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7784-3530","authenticated-orcid":false,"given":"Kian Guan","family":"Goh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miza Hiryanti","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja Nurazni","family":"Raja Azwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiren Kaur","family":"Bhajan Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hazrul","family":"Badrul Hisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanariah","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2022.102680_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3945\/ajcn.115.109553","article-title":"Health effects of intermittent fasting: hormesis of harm?","volume":"102","author":"Horne","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.dsx.2022.102680_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diabres.2017.07.014","article-title":"CREED study: hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents","volume":"132","author":"Jabbar","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108674","article-title":"The DAR 2020 Global survey: ramadan fasting during COVID 19 pandemic and the impact of older age on fasting among adults with Type 2 diabetes","volume":"173","author":"Hassanein","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib4","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2337\/diacare.27.10.2306","article-title":"A\u00a0population-based study of diabetes and its characteristics during the fasting month of ramadan in 13 countries: results of the epidemiology of diabetes and ramadan 1422\/2001 (EPIDIAR) study","volume":"27","author":"Salti","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102680_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.diabres.2019.03.031","article-title":"Attitude and safety of patients with diabetes observing the Ramadan fast","volume":"152","author":"Ba-Essa","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib6","volume":"185","author":"Hassanein","year":"2021","journal-title":"Diabetes and Ramadan: Practical guidelines"},{"key":"10.1016\/j.dsx.2022.102680_bib7","series-title":"National Health and morbidity survey 2015","author":"Aris","year":"2015"},{"key":"10.1016\/j.dsx.2022.102680_bib8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diabres.2019.02.020","article-title":"The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: an international prospective study (DAR-MENA T2DM)","volume":"151","author":"Hassanein","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib9","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"2117\u201328","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102680_bib10","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who with metformin plus sulfonylurea","volume":"1\u20139","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102680_bib11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes : results of an concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102680_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diabres.2017.04.004","article-title":"Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents","volume":"128","author":"Wang","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib13","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor\u2013associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.dsx.2022.102680_bib14","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis : a potential complication of treatment with sodium \u2013 glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102680_bib15","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors : basic mechanisms and therapeutic perspectives","volume":"1\u20139","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.dsx.2022.102680_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11606-008-0829-0","article-title":"Starvation-induced true diabetic euglycemic ketoacidosis in severe depression","volume":"24","author":"Joseph","year":"2008","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.dsx.2022.102680_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.diabres.2019.01.018","article-title":"The incidence of diabetic ketoacidosis during Ramadan fasting: a 10-year single-centre retrospective study","volume":"150","author":"Beshyah","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5001\/omj.2018.21","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2-I) during the month of ramadan in muslim patients with type 2 diabetes","volume":"33","author":"Bashier","year":"2018","journal-title":"Oman Med J"},{"key":"10.1016\/j.dsx.2022.102680_bib19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/dom.12649","article-title":"Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia","volume":"18","author":"Wan Seman","year":"2016","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102680_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.diabres.2018.05.022","article-title":"The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes","volume":"142","author":"Shao","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ggi.13149","article-title":"Use of sodium\u2013glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus","volume":"18","author":"Kambara","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.dsx.2022.102680_bib22","first-page":"21","article-title":"The effect of ramadan fasting on hemoglobin, hematocrit and blood biochemical parameters","volume":"6","author":"GhR","year":"2006","journal-title":"J\u00a0Res Health Sci"},{"key":"10.1016\/j.dsx.2022.102680_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.diabres.2019.04.010","article-title":"Design and development of the hypoglycaemia symptom rating questionnaire (HypoSRQ)","volume":"151","author":"Taylor","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Erondu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102680_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102680_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102680_bib27","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102680_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.diabres.2019.05.036","article-title":"Effect of Ramadan fasting on renal function in patients with type 2 diabetes","volume":"153","author":"Abushady","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib29","first-page":"1","article-title":"Fasting during the month of Ramadan among patients with chronic kidney disease: renal and cardiovascular outcomes","author":"Nasrallah","year":"2014","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.dsx.2022.102680_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.15537\/smj.2017.1.17566","article-title":"Effects of ramadan fasting on moderate to severe chronic kidney disease: a prospective observational study","volume":"38","author":"Bakhit","year":"2017","journal-title":"Saudi Med J"},{"key":"10.1016\/j.dsx.2022.102680_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12991","article-title":"Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during ramadan: results of the canagliflozin in ramadan tolerance observational study (CRATOS)","volume":"71","author":"Hassanein","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.ejcn.1602393","article-title":"Unexpected changes in blood pressure and hematological parameters among fasting and nonfasting workers during Ramadan in Indonesia","volume":"60","author":"Dewanti","year":"2006","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.dsx.2022.102680_bib33","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1017\/S1368980012005046","article-title":"Islamic fasting and weight loss: a systematic review and meta-analysis","volume":"17","author":"Sadeghirad","year":"2012","journal-title":"Publ Health Nutr"},{"key":"10.1016\/j.dsx.2022.102680_bib34","first-page":"377","article-title":"Weight change during and after Ramadan fasting","volume":"34","author":"Hajek","year":"2012","journal-title":"J\u00a0Public Heal (United Kingdom)"},{"key":"10.1016\/j.dsx.2022.102680_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2020.108465","article-title":"Use of SGLT2 inhibitors during Ramadan: an expert panel statement","volume":"169","author":"Hassanein","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102680_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.diabres.2019.02.027","article-title":"Risk of diabetic ketoacidosis during Ramadan fasting: a critical reappraisal","volume":"151","author":"Beshyah","year":"2019","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:21:49Z","timestamp":1761729709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122002971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1871402122002971"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102680","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of empagliflozin in patients with type 2 diabetes during Ramadan on volume status, ketonaemia, and hypoglycaemia","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102680"}}